{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-025983","form_type":"8-K","ticker":"MOVE","cik":"0001734750","company_name":"Corvex, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.058271+00:00","generated_at":"2026-06-25T18:51:41.095757+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Movano Q1 net loss $6.9M; validates SoC for glucose, BP; beta on track for 2H 2022","bullets":["Net loss of $6.9M ($0.21/share) vs $8.1M ($1.01/share) in Q1 2021; operating loss $6.9M.","Cash and investments $27.7M as of Mar 31, 2022, down from $33.6M at Dec 31, 2021.","Validated proprietary mmWave SoC for non-invasive glucose and cuffless blood pressure monitoring.","Hired go-to-market leadership team; added Nan Kirsten Forte to Board; plans limited beta release in 2H 2022.","No revenue generated; company remains development stage with R&D focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-025983","json":"https://secwatch.observer/filing/0001213900-22-025983.json","markdown":"https://secwatch.observer/filing/0001213900-22-025983.md","text":"https://secwatch.observer/filing/0001213900-22-025983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022025983/0001213900-22-025983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1734750/000121390022025983/ea159721-8k_movano.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T18:51:41.095757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}